Tratamiento de la colitis ulcerosa fulminante refractaria con anticuerpos quiméricos anti-CD25

[1]  B. Sandhu,et al.  Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease , 2010, Journal of pediatric gastroenterology and nutrition.

[2]  J. Fell,et al.  Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. , 2010, Journal of pediatric gastroenterology and nutrition.

[3]  C. Salinas,et al.  Eficacia y seguridad de tacrolimus oral para el tratamiento de la enfermedad inflamatoria intestinal pediátrica , 2009 .

[4]  V. V. Calderón,et al.  Infliximab como terapia de rescate en colitis ulcerosa grave resistente al tratamiento corticoideo , 2008 .

[5]  E. Ceriati,et al.  Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis , 2007, Langenbeck's Archives of Surgery.

[6]  N. Shepherd,et al.  Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease , 2006, Alimentary pharmacology & therapeutics.

[7]  J. Markowitz,et al.  Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. , 2006, Journal of pediatric gastroenterology and nutrition.

[8]  M. Dubinsky,et al.  Severe Colitis in Children , 2005, Journal of pediatric gastroenterology and nutrition.

[9]  R. Storb,et al.  Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Malago',et al.  Efficacy and tolerability of interleukin‐2 receptor blockade with basiliximab in pediatric renal transplant recipients , 2001, Pediatric transplantation.